The dynamics of the cell and gene therapies market in rare disorders are anticipated to change as companies across the globe are thoroughly working toward developing new therapeutic options to treat a wide array of indications.
LAS VEGAS, May 9, 2023 /PRNewswire/ -- DelveInsight's Cell and Gene Therapies in Rare Disorders Market Insights report includes a comprehensive understanding of current treatment practices, emerging cell and gene therapies for various rare disorders, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Cell and Gene Therapies in Rare Disorders Market Report
- As per DelveInsight analysis, the cell and gene therapies in rare disorders market size in the 7MM was approximately USD 1.5 billionin 2022.
- According to the assessment done by DelveInsight, the estimated total prevalent cases of selected indications for cell and gene therapies in rare disorders in the 7MM were approximately 900Kin 2022.
- Leading companies developing novel cell and gene therapies for various rare disorders, such as Hemophilia A, Hemophilia B, Fabry disease, Retinitis Pigmentosa, Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, and others include Roche, Freeline Therapeutics, Spark Therapeutics, Astellas Gene Therapies, Actus Therapeutics, GenSight Biologics, Coave Therapeutics, Johnson & Johnson, MeiraGTx, Applied Genetic Technologies Corporation, GenSight Biologics, Nanoscope Therapeutics, 4D Molecular Therapeutics, Ocugen, jCyte, ReNeuron, REGENXBIO, Amicus Therapeutics, Pfizer, Sarepta Therapeutics, Capricor Therapeutics, Nippon Shinyaku, Brainstorm Cell Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, Holostem Terapie Avanzate S.r.l., RHEACELL, Ishin Pharma, Anterogen, Ultragenyx Pharmaceutical, and others.
- The promising cell and gene therapies for various rare disorders in the pipeline include Giroctocogene fitelparvovec, Dirloctocogene samoparvovec, Fidanacogene elaparvovec, Verbrinacogene setparvovec (FLT-180a), FLT190, Isaralgagene civaparvovec (ST-920), 4D-310, SPK-3006, AT845, ACTUS-101, LUMEVOQ (lenadogene nolparvovec), CTx-PDE6b, Botaretigene sparoparvovec, ATGC-501 (laruparetigene zosaparvovec), GS030, MCO-010 (sonpiretigene isteparvovec), 4D-125, OCU400, jCell, RGX-121, AT-GTX-502 (scAAV9.P546.CLN3), PF-06939926, SRP-9001, CAP-1002, NurOwn (MSC-NTF cells), Exagamglogene autotemcel, EDIT-301, BIVV003, VYJUVEK (beremagene geperpavec), EB-101, D-Fi (dabocemagene autoficel), RV-LAMB3-transduced epidermal stem cells, Allogeneic ABCB5-positive Stem Cells, ISN001, ALLO-ASC-SHEET, DTX301, UX111 (ABO-102), DTX401 (AAV8G6PC), and others.
- In July 2022, the Institute for Clinical and Economic Review (ICER) released a final evidence report assessing the comparative clinical effectiveness and value of ZYNTEGLO (betibeglogene autotemcel) for treating beta-thalassemia.
- InMay 2022, Orchard Therapeutics reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV), which will result in reimbursed access to LIBMELDY (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients in Germany who fall within the scope of the European marketing authorization.
Discover which therapies are expected to grab the major cell and gene therapies in rare disorders market share @ Cell and Gene Therapies in Rare Disorders Market Report
Cell and Gene Therapies in Rare Disorders Overview
Cell and gene therapies use genes and cells to treat disease. A gene is a unit of DNA containing genetic information passed down from generation to generation. The genome comprises all genes; genes may contain information on observable features such as height or eye color. Many genes contain instructions for RNA or protein molecules that are not visible from the outside but serve crucial tasks in the body's cells. Cells are the building blocks of plants and animals (including humans); they are small functional units that work together to generate organs and tissues. Cell and gene therapy technology is quickly evolving for many different diseases. However, cell and gene treatments are still experimental drugs, and much more study is required before many of these therapies are available to patients worldwide.
Cell and Gene Therapies in Rare Disorders Epidemiology Segmentation
DelveInsight estimates that there were approximately 900K prevalent cases of selected indications for cell and gene therapies in rare disorders in the 7MM in 2022.
As per our analysis, the highest prevalent cases from the selected indications for cell and gene therapies in rare disorders were for Retinitis Pigmentosa in the United States, whereas the least cases were reported for Hunter Syndrome in 2022.
The cell and gene therapies in rare disorders market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Total Prevalent Cases of Shortlisted Indications for Cell and Gene Therapies in Rare Disorders
- Total Indication Eligible-wise Cases for Cell and Gene Therapies in Rare Disorders
- Indication-wise Treated Cases of Cell and Gene Therapies
Cell and Gene Therapies in Rare Disorders Market Insights
Numerous cell and gene therapies for rare diseases are currently approved in the 7MM, including retinitis pigmentosa (LUXTURNA), beta-thalassemia (ZYNTEGLO), epidermolysis bullosa (JACE), limbal stem cell deficiency (OCURAL), and many others. As per Delveinsight analysis, the total cell and gene therapies in rare disorders market size was around USD 1.5 billion in 2022. According to predictions, the United States will have the largest cell and gene therapies in rare disorders market. ZOLGENSMA produced the highest revenue of roughly USD 1 billion among the 7MM in 2022, while ROCTAVIAN is predicted to take the highest market share by 2032. ROCTAVIAN has received conditional approval in Europe for the treatment of severe hemophilia A. In addition to this approval, BioMarin Pharmaceutical is working to approve the drug in the United States, with a PDUFA target action date of June 30, 2023.
Hemophilia A is predicted to produce the most revenue among the selected indications by 2032, owing to the precedence of existing high treatment cost and expected high cost for emerging therapies along with significant residual unmet need. Gene treatments for Hemophilia A are estimated to earn around USD 6 billion in sales revenue by 2032 in the 7MM. The field of cell and gene therapies for rare indications is expected to rapidly expand in the coming years, as an increasing number of companies submit investigational new drug applications for these treatments each year, along with rising regulatory approval in the United States and Europe. In terms of manufacturing aspects of cell and gene therapies, there will be more competition for contract manufacturing businesses and pharmaceutical/biotechnology firms. The competition for contract manufacturing organization's production capacity will intensify as more companies enter the cell and gene therapy market, possibly driving up manufacturing costs. To ensure pharmaceutical/biotechnology firms can compete or obtain an advantage over competitors, companies may need to invest in manufacturing technologies or acquire companies with manufacturing expertise.
To know more about cell and gene therapies in rare disorders treatment guidelines, visit @ Cell and Gene Therapy Insights
Emerging Cell and Gene Therapies for Hemophilia A and Key Companies
- Giroctocogene fitelparvovec: Pfizer/Sangamo Therapeutics
- Dirloctocogene samoparvovec: Roche
Emerging Cell and Gene Therapies for Hemophilia B and Key Companies
- Fidanacogene elaparvovec: Pfizer/Spark Therapeutics
- Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
Emerging Cell and Gene Therapies for Fabry Disease and Key Companies
- FLT190: Freeline Therapeutics
- Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics
- 4D-310: 4D Molecular Therapeutics
Emerging Cell and Gene Therapies for Pompe Disease and Key Companies
- SPK-3006: Spark Therapeutics
- AT845: Astellas Gene Therapies
- ACTUS-101: Actus Therapeutics
Emerging Cell and Gene Therapies for Leber Hereditary Optic Neuropathy and Key Companies
- LUMEVOQ (lenadogene nolparvovec): GenSight Biologics
Emerging Cell and Gene Therapies for Retinitis Pigmentosa and Key Companies
- CTx-PDE6b: Coave Therapeutics
- Botaretigene sparoparvovec: Johnson & Johnson/ MeiraGTx
- ATGC-501 (laruparetigene zosaparvovec): Applied Genetic Technologies Corporation
- GS030: GenSight Biologics
- MCO-010 (sonpiretigene isteparvovec): Nanoscope Therapeutics
- 4D-125: 4D Molecular Therapeutics
- OCU400: Ocugen
- jCell: jCyte
Emerging Cell and Gene Therapies for Hunter Syndrome and Key Companies
- RGX-121: REGENXBIO
Emerging Cell and Gene Therapies for Batten Disease and Key Companies
- AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics
Emerging Cell and Gene Therapies for Duchenne Muscular Dystrophy (DMD) and Key Companies
- PF-06939926: Pfizer
- SRP-9001: Sarepta Therapeutics
- CAP-1002: Capricor Therapeutics/Nippon Shinyaku
Emerging Cell and Gene Therapies for Amyotrophic Lateral Sclerosis (ALS) and Key Companies
- NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
Emerging Cell and Gene Therapies for Beta Thalassemia and Sickle Cell Anemia and Key Companies
- Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals
- EDIT-301: Editas Medicine
- BIVV003: Sangamo Therapeutics
Emerging Cell and Gene Therapies for Dystrophic Epidermolysis Bullosa and Key Companies
- VYJUVEK (beremagene geperpavec): Krystal Biotech
- EB-101: Abeona Therapeutics
- D-Fi (dabocemagene autoficel): Castle Creek Biosciences
- RV-LAMB3-transduced epidermal stem cells: Holostem Terapie Avanzate S.r.l.
- Allogeneic ABCB5-positive Stem Cells: RHEACELL
- ISN001: Ishin Pharma
- ALLO-ASC-SHEET: Anterogen
Emerging Cell and Gene Therapies for Ornithine Transcarbamylase Deficiency and Key Companies
- DTX301: Ultragenyx Pharmaceutical
Emerging Cell and Gene Therapies for Sanfilippo Syndrome Type A and Key Companies
- UX111 (ABO-102): Ultragenyx Pharmaceutical
Emerging Cell and Gene Therapies for Glycogen Storage Disease Type IA and Key Companies
- DTX401 (AAV8G6PC): Ultragenyx Pharmaceutical
Learn more about the FDA-approved cell and gene therapies for rare disorders @ Approved Cell and Gene Therapies in Rare Disorders Treatment
Cell and Gene Therapies in Rare Disorders Market Dynamics
The cell and gene therapies in rare disorders market is predicted to grow positively due to an increase in the approval of a growing number of gene therapies and their ease of adoption following approval, the ability to treat a wide range of conditions, an increase in the number of cases, an expected one-time dosing approach, and curative treatment options.
The approval of LIBMELDY, SKYSONA, HOLOCLAR, UPSTAZA, ROCTAVIAN, and other medicines has successfully created regulatory channels for the development of further cell and gene therapies. Companies around the world are working hard to develop new cell and gene therapies options to treat a wide range of indications, such as hemophilia A and B, lysosomal storage disorder (Fabry, Pompe Disease, Danon Disease, MPS I, MPS II, MPS III), neurological disorders (Batten, Parkinson), musculoskeletal disorders (DMD, myotubular myopathy), eye diseases (achromatopsia, limbal stem cell deficiency, retinitis pigmentosa, retinoschisis, age-related macular degeneration, Leber's hereditary optic neuropathy), and other indications such as diabetic macular edema, inborn metabolism disorder (Wilson's disease, Phenylketonuria, OTC deficiency/urea cycle disorders), dystrophic epidermolysis bullosa, gangliosidosis, and xerostomia.
Many diseases' treatment landscapes have drastically evolved in the last few years. Companies are now developing cell and gene therapies that will play an important role in the future, particularly in the treatment of rare genetic disorders. The process of defining ideal candidates for given gene therapy and cell therapy will have to wait for the enrolment and long-term follow-up of a sufficient number of study subjects to provide satisfactory clarity regarding its safety and efficacy. In conclusion, the future of cell and gene therapy looks optimistic. Several clinical trials have yielded favorable results in terms of safety and efficacy. The findings of these studies motivate additional research into many indications, and the current scenario predicts a positive shift in the cell and gene therapies in rare disorders market for the forecast period.
However, several factors may impede the growth of cell and gene therapies in rare disorders market in the coming years. Despite advances since the enactment of the Orphan Drug Act, people in the United States with rare diseases continue to face challenges to diagnosis, care, and treatment. Moreover, in Europe, a possible crisis with gene treatments for rare diseases is developing, and few companies have withdrawn the drug after failing to get reimbursement in the EU.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Base Year | 2019 |
Cell and Gene Therapies in Rare Disorders Market CAGR | 35.8 % |
Cell and Gene Therapies in Rare Disorders Market Size in 2022 | USD 1.5 Billion |
Key Cell and Gene Therapies in Rare Disorders Companies | Roche, Freeline Therapeutics, Spark Therapeutics, Astellas Gene Therapies, Actus Therapeutics, GenSight Biologics, Coave Therapeutics, Johnson & Johnson, MeiraGTx, Applied Genetic Technologies Corporation, GenSight Biologics, Nanoscope Therapeutics, 4D Molecular Therapeutics, Ocugen, jCyte, ReNeuron, REGENXBIO, Amicus Therapeutics, Pfizer, Sarepta Therapeutics, Capricor Therapeutics, Nippon Shinyaku, Brainstorm Cell Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, Holostem Terapie Avanzate S.r.l., RHEACELL, Ishin Pharma, Anterogen, Ultragenyx Pharmaceutical, and others |
Key Pipeline Cell and Gene Therapies in Rare DisordersTherapies | Giroctocogene fitelparvovec, Dirloctocogene samoparvovec, Fidanacogene elaparvovec, Verbrinacogene setparvovec (FLT-180a), FLT190, Isaralgagene civaparvovec (ST-920), 4D-310, SPK-3006, AT845, ACTUS-101, LUMEVOQ (lenadogene nolparvovec), CTx-PDE6b, Botaretigene sparoparvovec, ATGC-501 (laruparetigene zosaparvovec), GS030, MCO-010 (sonpiretigene isteparvovec), 4D-125, OCU400, jCell, RGX-121, AT-GTX-502 (scAAV9.P546.CLN3), PF-06939926, SRP-9001, CAP-1002, NurOwn (MSC-NTF cells), Exagamglogene autotemcel, EDIT-301, BIVV003, VYJUVEK (beremagene geperpavec), EB-101, D-Fi (dabocemagene autoficel), RV-LAMB3-transduced epidermal stem cells, Allogeneic ABCB5-positive Stem Cells, ISN001, ALLO-ASC-SHEET, DTX301, UX111 (ABO-102), DTX401 (AAV8G6PC), and others |
Scope of the Cell and Gene Therapies in Rare Disorders Market Report
- Therapeutic Assessment: Cell and Gene Therapies in Rare Disorders current marketed and emerging therapies
- Cell and Gene Therapies in Rare DisordersMarket Dynamics: Conjoint Analysis of Emerging Cell and Gene Therapies in Rare Disorders Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's Views, Analyst's Views, Cell and Gene Therapies in Rare Disorders Market Access and Reimbursement
Discover more about cell and gene therapies for rare disorders in development @ Cell and Gene Therapy Clinical Trials
Table of Contents
1 | Cell and Gene Therapies in Rare Disorders Market Key Insights |
2 | Cell and Gene Therapies in Rare Disorders Market Report Introduction |
3 | Cell and Gene Therapies in Rare Disorders Market Key Highlights from Report |
4 | Executive Summary of Cell and Gene Therapies in Rare Disorders |
5 | Key Events: Cell and Gene Therapies in Rare Disorders |
6 | Cell and Gene Therapies in Rare Disorders Epidemiology and Market Forecast Methodology |
7 | Cell and Gene Therapies in Rare Disorders Market Overview at a Glance in the 7MM |
8 | Disease Background and Overview of Cell and Gene Therapies in Rare Disorders |
9 | Epidemiology and Patient Population |
10 | Marketed Cell and Gene Therapies in Rare Disorders |
10.1 | Key Competitors in Cell and Gene Therapies in Rare Disorders |
10.2 | Hemophilia A |
10.2.1 | ROCTAVIAN (valoctocogene roxaparvovec): BioMarin Pharmaceutical |
10.3 | Hemophilia B |
10.3.1 | HEMGENIX (etranacogene dezaparvovec): CSL Behring/uniQure |
10.4 | Retinitis Pigmentosa |
10.4.1 | LUXTURNA: Sparks Therapeutics (a company of Roche)/ Novartis |
10.5 | Spinal Muscular Atrophy (SMA) |
10.5.1 | ZOLGENSMA (onasemnogene abeparvovec-xioi): Novartis (AveXis) |
10.6 | Metachromatic Leukodystrophy (MLD) |
10.6.1 | LIBMELDY (atidarsagene autotemcel): Orchard Therapeutics |
10.7 | Limbal Stem Cell Deficiency |
10.7.1 | HOLOCLAR (Autologous human corneal epithelial cells containing stem cells): Holostem Terapie Avanzate S.r.l. |
10.7.2 | OCURAL: Japan Tissue Engineering |
10.7.3 | SAKRACY: Hirosaki Lifescience Innovation |
10.7.4 | NEPIC (EYE-01M): Japan Tissue Engineering |
10.8 | Adrenoleukodystrophy (ALD) |
10.8.1 | SKYSONA (elivaldogene autotemcel): bluebird bio |
10.9 | Beta Thalassemia |
10.9.1 | ZYNTEGLO (betibeglogene autotemcel): bluebird bio |
10.1 | Aromatic l-amino acid decarboxylase (AADC) deficiency |
10.10.1 | UPSTAZA (Eladocagene exuparvovec): PTC Therapeutics |
10.11 | Dystrophic Epidermolysis Bullosa |
10.11.1 | JACE (human epidermal cell sheet): Japan Tissue Engineering |
10.12 | Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency (ADA-SCID) |
10.12.1 | STRIMVELIS: Orchard Therapeutics |
11 | Emerging Drugs |
11.1 | Key Competitors |
11.2 | Hemophilia A |
11.2.1 | Giroctocogene fitelparvovec: Pfizer/Sangamo Therapeutics |
11.2.2 | Dirloctocogene samoparvovec: Roche (Spark Therapeutics) |
11.3 | Hemophilia B |
11.3.1 | Fidanacogene elaparvovec: Pfizer/Spark Therapeutics |
11.3.2 | Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics |
11.4 | Fabry Disease |
11.4.1 | FLT190: Freeline Therapeutics |
11.4.2 | Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics |
11.4.3 | 4D-310: 4D Molecular Therapeutics |
11.5 | Pompe Disease |
11.5.1 | SPK-3006: Spark Therapeutics (acquired by Roche) |
11.5.2 | AT845: Astellas Gene Therapies |
11.5.3 | ACTUS-101: Actus Therapeutics (Acquired by Bayer) |
11.6 | Leber Hereditary Optic Neuropathy |
11.6.1 | LUMEVOQ (lenadogene nolparvovec): GenSight Biologics |
11.7 | Retinitis Pigmentosa |
11.7.1 | CTx-PDE6b: Coave Therapeutics |
11.7.2 | Botaretigene sparoparvovec: Johnson & Johnson/ MeiraGTx |
11.7.3 | ATGC-501 (laruparetigene zosaparvovec): Applied Genetic Technologies Corporation |
11.7.4 | GS030: GenSight Biologics |
11.7.5 | MCO-010 (sonpiretigene isteparvovec): Nanoscope Therapeutics |
11.7.6 | 4D-125: 4D Molecular Therapeutics |
11.7.7 | OCU400: Ocugen |
11.7.8 | jCell: jCyte |
11.7.9 | Human Retinal Progenitor Cells (hRPC): ReNeuron |
11.8 | Hunter Syndrome |
11.8.1 | RGX-121: REGENXBIO |
11.9 | Batten Disease |
11.9.1 | AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics |
11.1 | Duchenne Muscular Dystrophy (DMD) |
11.10.1 | PF-06939926: Pfizer |
11.10.2 | SRP-9001: Sarepta Therapeutics |
11.10.3 | CAP-1002: Capricor Therapeutics/Nippon Shinyaku |
11.11 | Amyotrophic Lateral Sclerosis (ALS) |
11.11.1 | NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics |
11.12 | Beta Thalassemia and Sickle Cell Anemia |
11.12.1 | Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals |
11.12.2 | EDIT-301: Editas Medicine |
11.12.3 | BIVV003: Sangamo Therapeutics |
11.13 | Dystrophic Epidermolysis Bullosa |
11.13.1 | VYJUVEK (beremagene geperpavec): Krystal Biotech |
11.13.2 | EB-101: Abeona Therapeutics |
11.13.3 | D-Fi (dabocemagene autoficel): Castle Creek Biosciences |
11.13.4 | RV-LAMB3-transduced epidermal stem cells: Holostem Terapie Avanzate S.r.l. |
11.13.5 | Allogenic ABCB5-positive Stem Cells: RHEACELL |
11.13.6 | ISN001: Ishin Pharma |
11.13.7 | ALLO-ASC-SHEET: Anterogen |
11.14 | Ornithine transcarbamylase deficiency (OTC Deficiency) |
11.14.1 | DTX301: Ultragenyx Pharmaceutical |
11.15 | Sanfilippo syndrome type A (MPS IIIA) |
11.15.1 | UX111 (ABO-102): Ultragenyx Pharmaceutical |
11.16 | Glycogen Storage disease Type IA |
11.16.1 | DTX401 (AAV8G6PC): Ultragenyx Pharmaceutical |
12 | Cell and Gene Therapies in Rare Disorders: 7MM analysis |
12.1 | Key Findings |
12.2 | Market Outlook |
12.3 | Conjoint Analysis |
12.4 | Key Market Forecast Assumptions |
12.5 | Indication-wise Market size of Cell and Gene Therapies in Rare Disorders in the 7MM |
12.6 | Market Size of Cell and Gene Therapies in Rare Disorders by Therapies in the 7MM |
12.7 | United States Market Size |
12.8 | EU4 and the UK Market Size |
12.9 | Japan Market Size |
13 | Unmet Needs |
14 | SWOT Analysis |
15 | KOL Views |
16 | Market Access and Reimbursement |
17 | Appendix |
18 | DelveInsight Capabilities |
19 | Disclaimer |
20 | About DelveInsight |
Related Reports
Gene and Cell Therapies in Rare Disorder Epidemiology Forecast
Gene and Cell Therapies in Rare Disorder Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted gene and cell therapies in rare disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cell And Gene Therapy For Multiple Myeloma Market
Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy for multiple myeloma companies, including Pfizer, MorphoSys, Biokine Therapeutics, Arcellx, Rapa Therapeutics, among others.
Gene Therapy For Ocular Rare Disease Pipeline
Gene Therapy For Ocular Rare Disease Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy for ocular rare disease companies, including Roche Holding, Novartis, Ocugen, among others.
Adeno-Associated Virus Vectors in Gene Therapy Market
Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adeno-associated virus vectors in gene therapy companies, including Pfizer, CSL Behring, Spark Therapeutics, Freeline Therapeutics, RegenxBio, Amicus Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/significant-positive-shift-in-the-cell-and-gene-therapies-in-rare-disorders-market-with-35-8-cagr-during-the-study-period-2019-2032-expected-by-analysts-at-delveinsight-301819351.html
